Last reviewed · How we verify
Placebo for Adalimumab
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in Phase 3 clinical trial for adalimumab (TNF-alpha inhibitor).
At a glance
| Generic name | Placebo for Adalimumab |
|---|---|
| Also known as | placebo |
| Sponsor | Janssen Scientific Affairs, LLC |
| Modality | Biologic |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish baseline efficacy and safety of an active drug (in this case, adalimumab). Any observed effects in placebo recipients are attributed to the placebo effect—psychological and physiological responses to the expectation of treatment rather than the drug itself. Placebos are essential for blinded, randomized controlled trials to isolate the true therapeutic benefit of the investigational or active agent.
Approved indications
- Control arm in Phase 3 clinical trial for adalimumab (TNF-alpha inhibitor)
Common side effects
Key clinical trials
- An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD) (PHASE2)
- Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI (PHASE1, PHASE2)
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (PHASE3)
- Diabetes Islet Preservation Immune Treatment (PHASE1, PHASE2)
- Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (PHASE3)
- Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis (PHASE4)
- A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) (PHASE3)
- Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for Adalimumab CI brief — competitive landscape report
- Placebo for Adalimumab updates RSS · CI watch RSS
- Janssen Scientific Affairs, LLC portfolio CI